{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T08:42:09.776856+00:00","company":{"ticker":"CTMX","cik":1501989,"company_name":"CytomX Therapeutics, Inc."},"pagination":{"limit":100,"returned":13,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"material_agreement","fact_key":"13c6864d40bfd8db394db21fc67932cf3d86491e","cik":1501989,"ticker":"CTMX","company_name":"CytomX Therapeutics, Inc.","filed_at":"2026-06-03T20:15:15+00:00","payload":{"action":"amendment","agreement_name":"Amendment No. 4","agreement_type":"collaboration","counterparty":"Regeneron Pharmaceuticals, Inc.","effective_date":"2026-05-31","item_codes_triggered":["1.01"],"value_text":"Total potential target nomination payments and preclinical, clinical, regulatory and commercial mile"},"claim":"CytomX Therapeutics, Inc. amended Amendment No. 4 with Regeneron Pharmaceuticals, Inc. valued at Total potential target nomination payments and preclinical, clinical, regulatory and commercial mile (effective 2026-05-31).","evidence_excerpt":"On May 29, 2026, the Company and Regeneron entered into Amendment No. 4 to the Agreement (“Amendment No. 4”), effective May 31, 2026","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-255467","anchor_url":"https://secwatch.observer/filing/0001193125-26-255467#claim-13c6864d40bfd8db394db21fc67932cf3d86491e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312526255467/0001193125-26-255467-index.htm"},{"fact_type":"earnings_release","fact_key":"fd114a7d6583a6a52dcbcec76b5fd3d4d323bbbe","cik":1501989,"ticker":"CTMX","company_name":"CytomX Therapeutics, Inc.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"for the quarter ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":"10.3 million"},"claim":"CytomX Therapeutics, Inc. reported for the quarter ended March 31, 2026 results: revenue 10.3 million.","evidence_excerpt":"Total revenue was $10.3 million for the quarter ended March 31, 2026, compared to $50.9 million for the first quarter of 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-211920","anchor_url":"https://secwatch.observer/filing/0001193125-26-211920#claim-fd114a7d6583a6a52dcbcec76b5fd3d4d323bbbe","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312526211920/0001193125-26-211920-index.htm"},{"fact_type":"executive_change","fact_key":"0a3651eab5","cik":1501989,"ticker":"CTMX","company_name":"CytomX Therapeutics, Inc.","filed_at":"2025-02-03T23:59:59+00:00","payload":{"action":"terminated","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-07","interim":false,"role":"Senior Vice President, Chief Business Officer, and Head of Strategy","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Jeffrey Landau was terminated as Senior Vice President, Chief Business Officer, and Head of Strategy at CytomX Therapeutics, Inc..","evidence_excerpt":"On January 30, 2025, Jeffrey Landau, Senior Vice President, Chief Business Officer, and Head of Strategy, of CytomX Therapeutics, Inc. (the “Company”) and the Company agreed that Mr. Landau’s employment by the Company would terminate, effective February 7, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-019257","anchor_url":"https://secwatch.observer/filing/0001193125-25-019257#claim-0a3651eab5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312525019257/0001193125-25-019257-index.htm"},{"fact_type":"executive_change","fact_key":"f0f3699dbb","cik":1501989,"ticker":"CTMX","company_name":"CytomX Therapeutics, Inc.","filed_at":"2024-06-17T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-06-15","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Chris Ogden was appointed as Chief Financial Officer at CytomX Therapeutics, Inc..","evidence_excerpt":"On June 12, 2024, CytomX Therapeutics, Inc. (the “Company”) appointed Chris Ogden to serve as the Company’s Chief Financial Officer effective June 15, 2024 (the “Effective Date”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-162652","anchor_url":"https://secwatch.observer/filing/0001193125-24-162652#claim-f0f3699dbb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524162652/0001193125-24-162652-index.htm"},{"fact_type":"governance_change","fact_key":"cd71f4c4745645ec8a00e29463c09ace70e099c4","cik":1501989,"ticker":"CTMX","company_name":"CytomX Therapeutics, Inc.","filed_at":"2024-05-17T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-05-17","item_codes_triggered":["5.03"],"summary_text":"Increased authorized shares of common stock from 150,000,000 to 300,000,000 shares."},"claim":"CytomX Therapeutics, Inc.: Increased authorized shares of common stock from 150,000,000 to 300,000,000 shares (effective 2024-05-17).","evidence_excerpt":"On May 17, 2024, CytomX Therapeutics, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an Amended and Restated Certificate of Incorporation reflecting an amendment to increase the authorized number of shares of the Company’s common stock from 150,000,000 to 300,000,000 shares (the “Charter Amendment”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-24-141699","anchor_url":"https://secwatch.observer/filing/0001193125-24-141699#claim-cd71f4c4745645ec8a00e29463c09ace70e099c4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524141699/0001193125-24-141699-index.htm"},{"fact_type":"shareholder_vote","fact_key":"4de2c3da2427848f5ae03ea278bfbf3f4eb886ff","cik":1501989,"ticker":"CTMX","company_name":"CytomX Therapeutics, Inc.","filed_at":"2024-05-17T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-15","outcome":"passed","proposal_text":"Advisory vote on executive compensation","proposal_type":"say_on_pay","votes_abstain_text":"61,704","votes_against_text":"1,905,835","votes_for_text":"27,396,411"},"claim":"CytomX Therapeutics, Inc. shareholders approved Advisory vote on executive compensation at the 2024-05-15 meeting.","evidence_excerpt":"Proposal 4. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC. FOR AGAINST ABSTAIN BROKER NON-VOTES 27,396,411 1,905,835 61,704 17,554,723","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001193125-24-141699","anchor_url":"https://secwatch.observer/filing/0001193125-24-141699#claim-4de2c3da2427848f5ae03ea278bfbf3f4eb886ff","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524141699/0001193125-24-141699-index.htm"},{"fact_type":"shareholder_vote","fact_key":"6560b6f50e1918a1913d47fae33dee7b4d160133","cik":1501989,"ticker":"CTMX","company_name":"CytomX Therapeutics, Inc.","filed_at":"2024-05-17T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-15","outcome":"passed","proposal_text":"Amendment to increase authorized shares of common stock from 150,000,000 to 300,000,000","proposal_type":"charter_amendment","votes_abstain_text":"999,741","votes_against_text":"3,211,496","votes_for_text":"42,707,436"},"claim":"CytomX Therapeutics, Inc. shareholders approved Amendment to increase authorized shares of common stock from 150,000,000 to 300,000,000 at the 2024-05-15 meeting.","evidence_excerpt":"Proposal 3. The Company’s stockholders approved of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 shares to 300,000,000 shares. FOR AGAINST ABSTAIN 42,707,436 3,211,496 999,741","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001193125-24-141699","anchor_url":"https://secwatch.observer/filing/0001193125-24-141699#claim-6560b6f50e1918a1913d47fae33dee7b4d160133","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524141699/0001193125-24-141699-index.htm"},{"fact_type":"shareholder_vote","fact_key":"84007f2377ce107ffbc804776b397b63ec85e053","cik":1501989,"ticker":"CTMX","company_name":"CytomX Therapeutics, Inc.","filed_at":"2024-05-17T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-15","outcome":"passed","proposal_text":"Ratification of Ernst & Young LLP as independent registered public accounting firm","proposal_type":"auditor_ratification","votes_abstain_text":"26,853","votes_against_text":"369,346","votes_for_text":"46,522,474"},"claim":"CytomX Therapeutics, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm at the 2024-05-15 meeting.","evidence_excerpt":"Proposal 2. The Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. FOR AGAINST ABSTAIN 46,522,474 369,346 26,853","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001193125-24-141699","anchor_url":"https://secwatch.observer/filing/0001193125-24-141699#claim-84007f2377ce107ffbc804776b397b63ec85e053","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524141699/0001193125-24-141699-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f7ae2ae9044b16d49ab9b3139103b88de15627f5","cik":1501989,"ticker":"CTMX","company_name":"CytomX Therapeutics, Inc.","filed_at":"2024-05-17T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-15","outcome":"passed","proposal_text":"Election of Class III directors","proposal_type":"director_election","votes_abstain_text":"79,486","votes_against_text":"514,091","votes_for_text":"28,770,373"},"claim":"CytomX Therapeutics, Inc. shareholders approved Election of Class III directors at the 2024-05-15 meeting.","evidence_excerpt":"Proposal 1. The Company’s stockholders elected the Class III director nominees below to the Company’s Board of Directors to hold office until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or the earlier of their death, resignation or removal. NOMINEE FOR AGAINST ABSTAIN BROKER NON-VOTES Alan Ashworth, Ph.D., FRS 28,770,373 514,091 79,486 17,554,723 James R. Meyers 28,970,141 324,310 69,499 17,554,723 Halley Gilbert 24,008,423 5,271,685 83,842 17,554,723","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-141699","anchor_url":"https://secwatch.observer/filing/0001193125-24-141699#claim-f7ae2ae9044b16d49ab9b3139103b88de15627f5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524141699/0001193125-24-141699-index.htm"},{"fact_type":"earnings_release","fact_key":"853756d227f9fb4017cca72682799e8b1c429782","cik":1501989,"ticker":"CTMX","company_name":"CytomX Therapeutics, Inc.","filed_at":"2024-05-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter 2024","report_date":"2024-05-08","result_type":"reported_results","revenue_text":null},"claim":"CytomX Therapeutics, Inc. reported financial results for first quarter 2024.","evidence_excerpt":"On May 8, 2024, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its unaudited financial results as of and for the three months ended March 31, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-055598","anchor_url":"https://secwatch.observer/filing/0000950170-24-055598#claim-853756d227f9fb4017cca72682799e8b1c429782","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1501989/000095017024055598/0000950170-24-055598-index.htm"},{"fact_type":"governance_change","fact_key":"97db422f86bcb3d818a4d5f3b570f7ac4408a545","cik":1501989,"ticker":"CTMX","company_name":"CytomX Therapeutics, Inc.","filed_at":"2024-03-22T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2024-03-20","item_codes_triggered":["5.03"],"summary_text":"Amended and restated bylaws to modernize stockholder nomination and proposal procedures, remove 'acting in concert' provisions, and make clarifying changes."},"claim":"CytomX Therapeutics, Inc.: Amended and restated bylaws to modernize stockholder nomination and proposal procedures, remove 'acting in concert' provisions, and make clarifying changes (effective 2024-03-20).","evidence_excerpt":"On March 20, 2024, the Board unanimously adopted Amended and Restated Bylaws of the Company (the bylaws, as so amended and restated, the “Amended and Restated Bylaws”), effective immediately, to, among other things, modernize and enhance certain disclosure and procedural requirements related to stockholder nominations of directors and submissions of stockholder proposals regarding other business at stockholder meetings, including removing the “acting in concert” provisions previously contained in the Company’s bylaws, as well as certain other clarifying, technical and conforming changes.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-24-075211","anchor_url":"https://secwatch.observer/filing/0001193125-24-075211#claim-97db422f86bcb3d818a4d5f3b570f7ac4408a545","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524075211/0001193125-24-075211-index.htm"},{"fact_type":"executive_change","fact_key":"ed71c75ec4","cik":1501989,"ticker":"CTMX","company_name":"CytomX Therapeutics, Inc.","filed_at":"2024-03-22T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-03-20","interim":false,"role":"Class I director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Zhen Su was appointed as Class I director at CytomX Therapeutics, Inc..","evidence_excerpt":"On March 20, 2024, Zhen Su, M.D., M.B.A., was appointed to the Board of Directors (the “Board”) of CytomX Therapeutics, Inc. (the “Company”), effective March 20, 2024, as a Class I director, with an initial term expiring at the Company’s 2025 annual meeting of stockholders, filling a vacancy.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-075211","anchor_url":"https://secwatch.observer/filing/0001193125-24-075211#claim-ed71c75ec4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524075211/0001193125-24-075211-index.htm"},{"fact_type":"earnings_release","fact_key":"e3093bed8e172b3b4877fbf42ce262de7ee1c944","cik":1501989,"ticker":"CTMX","company_name":"CytomX Therapeutics, Inc.","filed_at":"2024-03-11T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the year ended December 31, 2023","report_date":"2024-03-11","result_type":"reported_results","revenue_text":null},"claim":"CytomX Therapeutics, Inc. reported financial results for the year ended December 31, 2023.","evidence_excerpt":"On March 11, 2024, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its financial results for the year ended December 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-029207","anchor_url":"https://secwatch.observer/filing/0000950170-24-029207#claim-e3093bed8e172b3b4877fbf42ce262de7ee1c944","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1501989/000095017024029207/0000950170-24-029207-index.htm"}]}